唯科科技 reported revenue of ¥1.40B for the period ended 2026-06-30, +28.8% year on year. Net income was ¥0.15B, a 10.7% net margin on a 29.1% gross margin. The largest revenue line is 注塑产品 at 48% of the total. Free cash flow for the period was ¥0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.40B | +28.8% |
| Gross profit | ¥0.41B | — |
| Operating income | ¥0.16B | — |
| Net income | ¥0.15B | -4.0% |
| Gross margin | 29.1% | Net margin 10.7% |
| Revenue Q/Q | +29.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 注塑产品 | ¥0.68B | 48.2% |
| 健康产品 | ¥0.44B | 31.3% |
| 精密模具 | ¥0.13B | 9.2% |
| 其他 | ¥0.08B | 5.9% |
| 汽车电子 | ¥0.08B | 5.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.99B | 70.9% |
| R&D | ¥0.06B | 4.6% |
| SG&A | ¥0.15B | 10.6% |
| Tax & other | ¥0.01B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥5.01B |
| Total liabilities | ¥1.46B |
| Shareholders' equity | ¥3.56B |
| Equity / assets | 71.0% |
| Operating cash flow | ¥0.09B |
| Capital expenditure | ¥0.06B |
| Free cash flow | ¥0.03B |
| Cash conversion (OCF / net income) | 146% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
工大科雅 ・ 喜悦智行 ・ 迈赫股份 ・ 大族数控 ・ 诚达药业 ・ 朗威股份 ・ 国泰环保 ・ 联特科技 ・ 三元生物 ・ 华兰疫苗 ・ 中亦科技 ・ 联合化学
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies